Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).Fabrice André, Komal Jhaveri, Joohyuk Sohn et al.|Journal of Clinical Oncology|2022Cited by 25
Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).Fabrice André, Komal Jhaveri, Erika Hamilton et al.|Journal of Clinical Oncology|2021Cited by 15